Non-adherence to medication and associated factors among type 2 diabetes patients at Clinique Medicale Fraternite, Rwanda: a cross-sectional study

Jean de Dieu Murwanashyaka¹*, Albert Ndagijimana¹, Emmanuel Biracyaza², François Xavier Sunday³ and Maryse Umugwaneza¹

Abstract

Background: Type 2 Diabetes Miletus (T2DM) is a public health burdens that alarmingly increases and leads to morbidity and mortality over the last decades globally. Its management is multifaceted and adherence to diabetic medications plays great roles in life of T2DM patients. But epidemiology on adherence and its associated factors remain unknown in Rwanda. Therefore, this study determined the extent of non-adherence and its predictors among T2DM patients seeking healthcare services at the Clinique Medicale la Fraternite.

Methods: A cross-sectional study among 200 adults’ patients with T2DM receiving care in the Medicales la Fraternite clinic was investigated. Bivariate and multivariate logistic regression models were performed based on odds ratio employed to examine associated predictors of non-adherence. The cut-off value for all statistical significances tests were considered at \( p < 0.05 \) with 95% for the confidence intervals.

Results: Overall, more than a half of T2DM patients (53.5%) had poor medication adherence. Being females [OR = 2.1, 95%CI(1.13–3.71), \( p = 0.002 \)], consuming anti-diabetic drugs for 4–10 years [OR = 2.18, 95%CI(1.09–4.34), \( p = 0.027 \)], experiencing poor communication with healthcare providers [OR = 2.4; 95%CI (1.36–4.25), \( p = 0.003 \)] and being perceived as burden of the family [OR = 5.8; 95%CI(1.3–25.7), \( p < 0.021 \)] had higher odds of non-adherence to anti-diabetic medications. Those with poor HbA1C [OR = 4.26; 95%CI(1.7–10.67), \( p = 0.002 \)] had 4.26 times higher odds to be non-adherent compared to those with good HbA1C. Respondents with primary [OR = 3.56; 95%CI (1.12–11.28), \( p = 0.031 \)] and secondary education [OR = 2.96; 95%CI (1.11–7.87), \( p = 0.03 \)] were more likely to be non-adherent than those with informal education respectively. Those with normal BMI [OR = 5.17; 95%CI(1.63–16.37), \( p = 0.005 \)] and those with overweight or obese [OR = 3.6; 95%CI (1.04–9.1), \( p < 0.02 \)] had higher odds of being non-adherent than those with underweight.

Conclusion: Sex, glycaemia, communication with healthcare providers, education and glycosylated hemoglobin were the major predictors of non-adherence. Interventions for tackling this problem through bringing together efforts to stem this epidemic and controlling predictors of non-adherence are urgently recommended.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Keywords: Diabetes Mellitus, Adherence, Prevalence, Medication, Prescribed

Background

Type II Diabetes Mellitus (T2DM) refers to a group of heterogeneous disorders with the common elements of chronic hyperglycemia and glucose intolerance due to insulin deficiency, impaired effectiveness of insulin action, or both [1, 2]. The prevalence of T2DM continues increasing dramatically in developed and developing countries [2, 3]. This disease accounts for approximately 90% of all patients (347 million cases globally) with diabetes worldwide [4–6]. Although approximately 4% of overall global deaths of T2DM occur, more than 80% of mortality occurs in the low-and middle-income countries (LMICs) [7, 8]. Additionally, the management of this chronic metabolic disease incurs remarkable a burden due to its diverse complications and outcomes largely attributed to non-adherence to anti-diabetic medications that remain a concern [9, 10]. The World Health Organization (WHO) projected that by 2040, 8.5% of the world’s population (more than 642 million patients with diabetes) will have T2DM in comparison to 4.7% in 1980s [11, 12]. Between 2010 and 2030, the number of adults is expected to rise up to 69% in developing countries and by 20% in industrial countries of the world [7, 13]. Thus, there is an increase of biopsychophysiological conditions as outcomes of T2DM and negative attitudes (such discrimination, social rejection, blame, stigmatise, discouraging patients) of the family members towards their T2DM patients. These attitudes may lead to worse health outcome for the patients or cause feelings of fear, embarrassment, anxiety, low self-esteem, guilt and blame [14, 15].

In the case that patients with T2DM do not adhere to medications, serious effects may arise, such as disease relapse and progression [16]. In Sub-Saharan African (SSA) countries such as in Uganda, Burundi, Tanzania and Kenya, non-adherence to anti-diabetic drugs is debatable and a continuation of this concern was documented [17, 18], if no preventive measures are not taken for decreasing its factors [19–24]. Rwanda has experienced an increase of the morbidity of the diabetes and this has reached to more than 2% among overall deaths [25]. Besides, T2DM is caused by behavioral influences compromising poor diet, lack of physical exercises, obesity, use of alcohol, and drugs. Although almost factors are related to lifestyle habits of the individuals, environmental influences (internal environmental factors like inflammatory and adipocytokines and hepatocyte factors; external environmental factors like endocrine disruption) and genetic influences are established [26, 27]. Other contributing factors to T2DM include fat distribution, family history, pre-diabetes and gestational diabetes [20, 28].

Adherence to anti-diabetic medications refers to the extent to which an individual’s medication use behaviour coincides with medical advice, and persistence as the duration of time from initiation to discontinuation of therapies [29, 30]. The WHO in its landmark report on non-adherence globally estimated 50% adherence to T2DM medications and further stated that adherence was more likely to lower in developing countries owing to resource limitations [12, 31, 32]. Thus, non-adherence to anti-diabetic medications varies from 36 to 93% [33, 34] and this can alter the level of blood glucose and causes the complications that weaken the quality of life [35]. Further, more than a half of patients with T2DM have poor glycemic control [36] and this burden exacerbate life in the countries from East Africa like Ethiopia [35], Tanzania, Uganda and Kenya [37, 38]. More, high cost of anti-diabetic drugs, long duration of taking medications, side effects of anti-diabetic drugs such as fatigue, nausea, vomiting, psychological problems and itching, socio-cultural issues, substance use, health literacy, belief, availability and affordability of insulin, and non-persistence are factors of non-adherence [7, 39, 40]. Previous studies identified factors of non-adherence such as poorer treatment outcomes, low demographic characteristics (like young age, lower education and income), progression of disease symptoms and complications [10, 28]. Optimal glucose control can be achieved through strict compliance to medications, diet, and lifestyle modifications, which in turn minimize long-term complications [41–44]. This results in encountering difficulties to maintain the desired level of required glycaemia [45–47].

Earlier studies agreed that the adherence to anti-diabetic drugs plays crucial roles in promoting quality of life of patients and this prevents long-term harmful effects [48, 49]. In the region of East Africa, socio-demographic and behavioral problems were reported as factors contributing to adherence to anti-diabetic drugs. For example, in Ethiopia, Kenya and Tanzania stated that the prevalence of non-adherence varies from 17.5% to 28.9% [50, 51]. Among the factors leading to non-adherence to anti-diabetic medications, types of medications were documented [40, 52]. For instance; patients under insulin experience non-adherence because medications of insulin and its available remain challenge in most countries when compared to OHA [53, 54]. So, non-adherence to T2DM drugs was described as a product of the
interaction between patient-related factors (like demographic and psychosocial factors), disease-related factors (such as comorbidities, blood glucose monitoring and complications) and medical system [55, 56].

According to several previous studies, better adherence with older patients while others reported younger patients as being more adherent to medications [37, 57]. Further, psychological influence on adherence where patients with diabetes with stigma, depression, eating disorders, and anxiety develop a higher risk to poor adherence to medications [8, 58]. Pertaining to diabetics, treatment-related barriers and negative emotions contribute to lack of success in reducing HbA1C [59, 60]. In addition, problems with adherence are cyclical in that poor adherence may lead to poor glycemic control, which creates treatment-oriented frustration [38, 61]. Moreover, non-adherence is influenced by the factors like the number of medications (pills burden), cost for medications, side effects, dosage frequency, dosage regimens [62–64]. Hence, having regular and frequent contact with patients by telephone promoted regimen adherence and achieved improvements in glycemic control, as well as in lipid and blood pressure levels contribute to adherence [56, 65]. The Diabetes Atlas reported an expected dramatic increase of T2DM from 3.2% and this makes it one of national pestilence [25, 66]. Non-adherence to prescribed anti-diabetic drugs is also controversial and there is a need to attenuate the factors contributing to non-adherence to drugs [67]. Though the non-adherence remains a public health concern in Rwanda, there is a gap in knowledge about prevalence of non-adherence to anti-diabetic medications and its predictors in Rwanda. With this background and gap, this study determined the prevalence of non-adherence to anti-diabetic medications and its associated predictors in the Clinique Medicale Fraternite. The results of this study are expected to guide the development of effective and customized strategies to enhance patients’ medication adherence and improve their diabetes outcomes in the long term.

**Conceptual framework**

Our conceptual framework developed based on the factors associated with non-adherence in T2DM patients that were documented in previous epidemiological studies. Those factors compromise socio-economic and demographic factors (such as age, sex, marital status, monthly income, employment status, education, residence, religion, traditional medications, attitudes towards T2DM patients (such as stigmatisation, social rejection, discouraging them, blame, feeling concerned in disease management, feeling well concerned, feeling that the T2DM patient is the burden for the family), patient to doctor communication); anthropometric and clinical characteristics (such as blood pressure, Body Mass Index, glycosylated haemoglobin, glycaemia level); and complications due to T2DM, retinopathy or any other eye disease, kidney disease, skin infection and other chronic disease (Fig. 1).

**Methods**

**Study design and settings**

Institutional cross-sectional study design was conducted among 200 hospitalized and ambulatory patients diagnosed T2DM at the Clinique Medicale Fraternite.

---

**Fig. 1** Conceptual framework. Abbreviations: BMI: Body Mass Index, HbA1C: Glycosylated haemoglobin, T2DM: Type 2 Diabetic Mellitus, g/dL: gram per decilitre; kg/m²: Kilogram per square metre
Clinique Medicale Fraternite is the clinic Kigali city, capital of Rwanda and specialized in providing healthcare among patients with diabetes in Rwanda. This clinic was found in 1997 and serves as one of important health facilities for diabetes in Rwanda. It is also the only national specialized diabetes clinical in Rwanda as established by the Rwandan Diabetes Association (RDA). Its staff is composed of doctors and nurses who work for providing healthcare for the patients with diabetes. More than 12,000 patients have been screened for diabetes at the clinic which has its own laboratory with an HbA1C machine. More than 6000 patients with diabetes are currently registered at the clinic, while others follow treatment in the hospitals. The clinic has six beds and a trained diabetes nurse present 24 h [66]. It also operates from 24 h daily and delivers the anti-diabetic treatments and medical follow-up for the patients with T2DM.

Study population and sample size

The participants were patients diagnosed and treated T2DM. Our study enrolled adult patients, diagnosed and confirmed as patient at least 6 months prior to the study start, and those with willingness and ability to participate. All eligible participants were registered by the RDA. The exclusion criteria were having several health conditions including cognitive impairments, not providing written consent forms for participating, having severe hearing and visual impairments, and lack of voluntariness in participating. Then, sample size was calculated using single proportion formula [68] considering a 95% (z = 9.16) confidence intervals, 5% margin error (e = 0.05) and a known prevalence of non-adherence (p = 34%) or 0.34 to diabetic medication among patients from surrounding country of Rwanda [69]. This resulted in a calculated sample size of 336 patients.

\[ n = \frac{1.96^2 \times 0.34(1 - 0.34)}{0.05^2} = 336 \]

Data collection and sampling techniques

A convenient sampling technique was employed for participant recruitment. Data collectors were provided the list of the potential participants and when the patient came at the appointment was given the list to check if they were eligible to participate. Then, the interested participants who accepted voluntarily to participate in the study were given a copy of their current medication list record and then referred to the research for taking part in the interview. Before interview, the researcher brought the respondents in the private area for explaining to them about the research. Further, data collection was performed from March 1, 2019 to September 30, 2019 by trained data collectors whose educational background was nursing and public health. After a short term-training deliver to the data collectors, data collection was conducted under coordination of the authors. Data were collected from the diabetic clinic day when the patients came for seeking health interventions. Participants completed the entire survey between 25 and 45 min.

Socio-demographic characteristics and clinical data

Socio-demographic questionnaire included variables such as age, residence, sex, employment status, religion, marital status, monthly income, education, use of traditional medications and attitudes towards patients with T2DM.

Patient-Doctor Communication Inventory (PDCI)

The PDCI is the 7-item psychometric instrument used to assess the level of communication between the doctor and patient [70, 71]. This measurement was designed since communication has a prominent contribution to patient satisfaction and adherence to medication prescribed by the healthcare provider. Communication also helps the patient to understand the diagnosis and treatment that also has an impact on care, have a relevant expectation and involvement in their treatments [72]. This instrument is mostly used in medication settings and has items the scored using 5-point Likert Scale (1 = never to 5 = always). After scores, each item the total scores are calculated and then are averaged into a single synthetic score reflecting overall performance. In our studies, PDCI has a satisfactory internal consistency (Cronbach’s Alpha, \( \alpha = 0.89 \)) as it is described in the previous studies [71].

Morisky-Green-Levine Scale (MGLS)

In the present study, the four-item Morisky Medication Adherence Scale (MGLS), which includes four questions with yes/no response options was used to measure the level of the adherence to anti-diabetic medication [73, 74]. The total scores of this instrument vary from 0 to 4. This MGLS is the medical measurement scored using bivariate (0 = no, 1 = yes) to assess the level of the adherence to medical drugs. The score of 4 indicated the high level of adherence [75]. The MGLS results also developers suggested three levels of adherence to the medications based on these scores: high, medium and low adherence with 0, 1, 2, and 3–4 points respectively. Further, the Alpha of Cronbach of this instrument was adequate (\( \alpha = 0.61 \)). Its cut-off is 3 is used for indicating that those with 3 score or more are non-adhered. The internal consistency of MGLS was adequate [74, 76]. Additionally, the MGLS had a dichotomous definition of adherence based on MGLS is also commonly used with 0 points indicating perfect adherence and 1 + points indicating some level
of non-adherence [74, 76, 77]. In our study, MGLS has an acceptable internal consistency (Alpha of Cronbach, α = 0.88).

**Anthropometric status and clinical data**

With the data of height, Body Mass Index (BMI) was performed. Height of the participants was measured without shoes to the nearest of 0.1 cm (cm) using the stand-meter whereas the weight was measured using the nearest of 0.1 kg on a hospital scale with the eligible patients to participate in the study who were wearing one-layer of the clothes and without shoes for avoiding the overestimation. The BMI was computed by taking the weight (kg) divided by the square of the height (m²). In this study, three categories of the BMI were demonstrated by using the recommended cut-offs where BMI < 18.5 kg/m² indicated underweight; BMI ≥ 18.5 kg/m² - 24.9 kg/m² was for patients with normal BMI; BMI ≥ 25 kg/m² indicated overweight whereas BMI ≥ 30 kg/m² indicated obesity [78]. Regarding clinical data, data about medication regimen such as number of medications, biomedical (blood pressure, glycosylated hemoglobin, level of glycemia), duration of disease, route of administration, type of medication, dosage frequencies, and complications status were collected. Additionally complications such as diagnosis of retinopathy, eye disease, skin infection, kidney disease, and other chronic disease were clinically collected.

**Data analysis**

Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) version 24. The statistical parameters for descriptive analysis included frequency, means and standard deviation to describe the participants and report the prevalence of non-adherence. In analytical analysis, bivariate and multivariate logistic regressions based on the odds ratio (OR) were employed to determine the associated factors of non-adherence to T2DM medications. Using the Database of this study, the internal consistent reliability using the Alpha of Cronbach was computed to indicate the consistency of the psychometric measures we used. Certainly, the Chi-square test was computed to measure the statistical significance of the association between the outcome and independent variables. The 95% confidence intervals and significance levels of p < 0.05 were statistically respected.

**Ethical considerations**

All methods were conducted in accordance with the tenets or regulations and principles of Helsinki Declaration [79]. Ethical approval was obtained from the Institutional Review Board, College of Medicine and Health Sciences at the University of Rwanda (N°: 460/CMHS IRB/2019). Authors were authorized by the staff of the Clinique Medicale Fraternite to collect data. Also, the permission to use MGLS was sought from Morisky-Green-Levine as required. Confidentiality was ensured. Participants provided the informed consent forms to participate.

**Results**

**Socio-demographic characteristics of the participants**

Among 336 eligible patients, only 212 (63.1%) participants took part in the study. A completion rate of 94.3% (n = 200) was achieved after excluding those whose data were incomplete and those who denied participating in the study. The main reasons for refusing to participate among 124 participants were lack of interest (n = 9), lack of time (n = 27), not feeling well on the day of the day collection (n = 46), complaint of compensation of taking part in the study (n = 32), and unknown reasons (n = 10). A majority of respondents (59.5%) were aged 50 years and above. The majority of the participants attended primary schools (51%) while 21% had not obtained any formal education. Concerning the employment status, the results of this study found the majority were unemployed (42.5%) whilst 18.5% and 39% worked in public institutions and private sectors respectively. The results represented the majority of the respondents were Christians who represented 74.5% of the sample. The 81.5% of the participants who were enrolled were from Kigali city while 18.5% were from the other settings out of Kigali. About monthly income, majority (52.5%) of the participants received less than 100,000rwf (Table 1).

**Anthropometric measurements and clinical records of the patients with T2DM**

The results indicated that among majority of the participants (57%) had normal blood pressure. Glycemic control as determined by HbA1C was poor (>7%) for 163 (81.5%) participants who participated in this research while only 18.5% represented good glycemic level. Findings indicated the patients with diabetes had different levels of BMI where majority of them had normal BMI (37%), and only 34% and 19% were overweight and obese. Concerning the medical complications, the results showed that 53% of the patients with diabetes had retinopathy, 26% kidney disease, 40% skin infection and 49% for other chronic diseases. The overall Alpha of Cronbach of DPCI was 0.76 indicating a satisfactory level of internal consistency (Table 2).

**Attitudes of the family members towards the patients with T2DM**

The results indicated that the patients who were enrolled in this study were from the family that had different attitudes towards the patients with the T2DM. It was found that the majority (40%) of the patients were from the
families whose members were very concerned to the diagnosed diseases and its management. This was followed by 35.5% of those who declared that their family members were not concerned to their disease. But, only 24.5% of T2DM were from the families that perceived them as their burdens or burdensome (Fig. 2).

Prevalence of medication non-adherence using MGLS
The prevalence of the adherence among the patients with T2DM using MGLS was calculated and our findings indicated that the prevalence of non-adherence to anti-diabetic medications was 53.5% [95%CI(47–60)], representing 107 patients with diabetes (Fig. 3).

### Table 1  Socio-demographic characteristics of the participants

| Variables                  | Frequency | Percentage |
|----------------------------|-----------|------------|
| Age                        |           |            |
| 18–30 years                | 10        | 5          |
| 31–50 years                | 71        | 35.5       |
| More than 50 years         | 119       | 59.5       |
| Sex                        |           |            |
| Male                       | 94        | 47         |
| Female                     | 106       | 53         |
| Marital Status             |           |            |
| Single                     | 24        | 12         |
| Married/cohabiting         | 145       | 72.5       |
| Divorce/widowed/widow      | 31        | 15.5       |
| Education                  |           |            |
| No formal education        | 42        | 21         |
| Primary                    | 102       | 51         |
| Secondary/higher/university| 56        | 28         |
| Employment status          |           |            |
| Unemployed                 | 85        | 42.5       |
| Public sectors             | 37        | 18.5       |
| Private sectors and others (e.g., business, farmers, livestock etc.) | 78 | 39 |
| Religion                   |           |            |
| Christians                 | 149       | 74.5       |
| Muslim and others          | 51        | 25.5       |
| Residence                  |           |            |
| Gasabo                     | 59        | 29.5       |
| Nyarugenge                 | 52        | 26         |
| Kicukiro                   | 52        | 26         |
| Out of Kigali              | 37        | 18.5       |
| Monthly income             |           |            |
| < 1000000rwf               | 105       | 52.5       |
| 100,000–200,000rwf         | 69        | 34.5       |
| > 2000000rwf               | 26        | 13         |
| Patient Doctor Communication Inventory (PDCI) | | |
| Poor communication         | 89        | 44.5       |
| Good communication         | 111       | 55.5       |

### Table 2  Anthropometric measures and clinical characteristics of the participants

| Variables                                | Frequency | Percentage |
|------------------------------------------|-----------|------------|
| Blood pressure                           |           |            |
| Normal                                   | 114       | 57         |
| Hypertension                             | 86        | 43         |
| BMI                                       |           |            |
| Underweight (< 18.5)                     | 20        | 10         |
| Normal (18.5–24.9)                       | 74        | 37         |
| Overweight (25–29.9)                     | 68        | 34         |
| Obese (30 and more)                      | 38        | 19         |
| Glycosylated Hemoglobin (HbA1C)          |           |            |
| Good(= <7%)                              | 37        | 18.5       |
| Poor (> 7%)                              | 163       | 81.5       |
| Glycemia (g/dl)                          |           |            |
| Less than 170 g/dl                       | 33        | 16.5       |
| 170–250 g/dl                             | 47        | 23.5       |
| More than 250 g/dl                       | 120       | 60         |
| Presence of diabetes complications      |           |            |
| Retinopathy                              |           |            |
| Yes                                      | 106       | 53         |
| No                                       | 94        | 47         |
| Kidney disease                           |           |            |
| Yes                                      | 52        | 26         |
| No                                       | 148       | 74         |
| Skin infection                           |           |            |
| Yes                                      | 80        | 40         |
| No                                       | 120       | 60         |
| Presence of other chronic disease        |           |            |
| Yes                                      | 99        | 49.5       |
| No                                       | 101       | 50.5       |

Association between different factors and non-adherence among the patients with T2DM
Our findings presented significant associated factors of non-adherence such as socio-demographic factors (such as sex, education, employment, and residence of the diabetic patient), clinical records (like BMI, medical drugs, duration of diabetes, glycaemia, DPCS, HbA1C) and diseases complications such as skin infections, and retinopathy. Bivariate analysis indicated the following variables are significantly associated with the non-adherence to anti-diabetic drugs; sex ($p = 0.032$), duration of diabetes ($p = 0.031$), education ($p = 0.036$), employment status ($p = 0.008$), residence of the patient ($p = 0.021$), medical drugs ($p = 0.027$), glycaemia level ($p = 0.046$), BMI ($p = 0.029$), retinopathy ($p = 0.052$), DPCI ($p = 0.003$),
skin infection \( (p = 0.035) \), and HbA1C \( (p = 0.013) \) (Table 3).

Our results that the following variables are significantly associated with the adherence to anti-diabetic drugs, medical drugs \( (p = 0.027) \), glycaemia level \( (p = 0.046) \), BMI \( (p = 0.029) \), retinopathy \( (p = 0.052) \), DPC I \( (p = 0.003) \), skin infection \( (p = 0.035) \), and HbA1C \( (p = 0.013) \) (Table 4).

Multivariate logistic regression models for the factors of non-adherence to medications

The results showed that the females were found to have a greater odd to be non-adhered to medications \( [OR = 2.18; 95\% CI(1.013–4.69), p = 0.046] \) than the males. Those who spent 4-10 years under anti-diabetic drugs were more likely to be non-adherent to medications \( (OR = 2.5, 95\% CI = 1.04–6.37) \) compared to who spent less than 4 years under anti-diabetic medications. Further, patients who studied primary \( [OR = 3.56; 95\% CI(1.12–11.23), p = 0.031] \) and secondary schools \( [OR = 2.96; 95\% CI(1.11–7.87), p = 0.03] \) were more likely to develop poor adherence to medications when compared to those with no formal education. Respondents with normal BMI had greater odds to be non-adherent \( [OR = 5.17; 95\% CI(1.63–16.37), p = 0.005] \) than those with underweight while those with overweight or obese were almost 4 time more likely to be non-adherent \( [OR = 3.6; 95\% CI (1.04–9.1), p < 0.02] \) than the patients with underweight. Respondents under OHA and insulin medications were less likely to be non-adherent than the patients under single OHA \( [OR = 0.59; 95\% CI(0.24–1.42), p = 0.023] \) and the patients under insulin only were less likely to be non-adherent \( [OR = 0.26; 95\% CI(0.09–0.74), p = 0.011] \) compared to the patients under single OHA. Patients who experienced a poor communication with the healthcare provider were more likely to experience non-adherence to medications \( [OR = 2.18; 95\% CI (1.013–4.69), p = 0.046] \) than their counterparts. Patients with diabetes with poor HbA1C were less likely to be non-adherent \( [OR = 4.26; 95\% CI(1.7–10.67), p = 0.002] \) than their counterparts. Those with 170-250 g/dl of glycaemia were more likely to be non-adherent \( [OR = 3.17; 95\% CI(1.06–9.5), p = 0.045] \) compared to the T2DM who had < 170 g/dl of glycaemia. The patients with skin infections had less chances to be non-adherent \( [OR = 0.36; 95\% CI(0.17–0.77), p = 0.009] \) than their counterparts (Table 5).

Discussion

The current study determined the prevalence of non-adherence to anti-diabetic medications and its associated factors among T2DM patients at Clinique Medical Fraternite. This study demonstrated that about 53.5% of the participants had non-adherence to medications. This result is similar to the study that was conducted in Cameroun [40]. Perhaps this similarity was because the study design used in our study is similar to the

- **Fig. 2** Attitudes of the family members towards to patients with T2DM. Very concerned: Refers to the family members who perceive well the T2DM and remains concerned in management of this disease; Not concerned: Refers to those who are not concerned about the T2DM; Perceived as burdensome: This refers to the family members who consider the T2DM as the burden of the family

- **Fig. 3** Prevalence of non-adherence to anti-diabetic medications

- **Table 3**

- **Table 4**

- **Table 5**
### Table 3: Bivariate logistic analyses of association between socio-demographic characteristics and non-adherence among patients with T2DM

| Variables                                | Non-adherence | Odd ratios, 95% CI | P-value |
|------------------------------------------|---------------|--------------------|---------|
|                                          | N  | %   | OR | Lower | upper |
| **Age**                                  |    |     |    |       |       |
| 18–30 years                              | 3  | 2.8 | 1  |       |       |
| 31–50 years                              | 40 | 37.38 | 2.71 | 0.670 | 11.01 | 0.16 |
| More than 50 years                        | 64 | 59.81 | 0.9 | 0.499 | 1.63 | 0.73 |
| **Sex**                                  |    |     |    |       |       |
| Male                                     | 47 | 43.93 | 1  |       |       |
| Female                                   | 60 | 56.07 | 1.85 | 1.05 | 3.24 | 0.032* |
| **Marital Status**                       |    |     |    |       |       |
| Single                                   | 9  | 8.41 | 1  |       |       |
| Married/cohabiting                       | 81 | 75.70 | 2.02 | 0.682 | 6.01 | 0.204 |
| Divorce                                  | 17 | 15.89 | 0.96 | 0.44 | 2.1  | 0.917 |
| **Duration with diabetes and medications** |    |     |    |       |       |
| 1-3 years                                | 49 | 45.79 | 1  |       |       |
| 4-10yrs                                  | 26 | 24.3 | 2.18 | 1.09 | 4.34 | 0.027* |
| More than 10 years                       | 32 | 29.91 | 1.03 | 0.43 | 2.42 | 0.954 |
| **Education**                            |    |     |    |       |       |
| No formal education                      | 17 | 15.89 | 1  |       |       |
| Primary                                  | 51 | 47.66 | 2.87 | 1.27 | 6.5  | 0.012* |
| Secondary                                | 39 | 36.45 | 1.834 | 0.94 | 3.58 | 0.075 |
| **Employment status**                    |    |     |    |       |       |
| Jobless                                  | 28 | 26.17 | 1  |       |       |
| Public employee                          | 28 | 26.17 | 2.36 | 1.24 | 4.48 | 0.009* |
| Private                                  | 51 | 47.66 | 0.8 | 0.38 | 1.72 | 0.57 |
| **Religion**                             |    |     |    |       |       |
| Christian                                | 83 | 77.57 | 1  |       |       |
| Muslim                                   | 21 | 19.63 | 0.477 | 0.11 | 2.07 | 0.323 |
| Other                                    | 3  | 2.80 | 0.629 | 0.13 | 2.97 | 0.557 |
| **Residence**                            |    |     |    |       |       |
| Kigali                                   | 76 | 71.03 | 1  |       |       |
| Out of Kigali                            | 31 | 28.97 | 2.3 | 1.14 | 4.660 | 0.021* |
| **DPCS**                                 |    |     |    |       |       |
| Good communication                       | 37 | 34.58 | 2.3 | 1.14 | 4.660 | 0.003** |
| Poor communication                       | 70 | 65.42 | 2.4 | 1.36 | 4.25 |
| **Attitudes of the family members towards patients with T2DM** |    |     |    |       |       |
| Very concerned                           | 46 | 42.99 | 1  |       |       |
| Not concerned                            | 37 | 34.58 | 0.5 | 0.21 | 12  | 0.23 |
| Perceived as burdensome                  | 24 | 22.43 | 4.8 | 1.2 | 19.8 | 0.032* |
| **Monthly income**                       |    |     |    |       |       |
| < 100,000rwf                             | 56 | 52.34 | 1  |       |       |
| 100,001–200,000rwf                        | 36 | 33.64 | 1.19 | 0.5 | 2.84 | 0.69 |
| > 200,000rwf                             | 15 | 14.02 | 1.25 | 0.5 | 3.11 | 0.63 |

* N indicates number of cases or frequency, % Percentage, OR Odds ratio, CI Confidence Intervals

*p < 0.05

**p < 0.01

***p < 0.001

*p < 0.05

**p < 0.01

***p < 0.001
study design used in this study. Also, our results stated that the prevalence on non-adherence is higher than the prevalence documented in the previous studies in the Switzerland, Tanzania, Ethiopia, and Kenya [31, 37, 39, 69], however, one few studies reported a higher prevalence of non-adherence to diabetic medication in Ethiopia than ours [17].

In coincide with the elsewhere studies that indicated that the socio-demographic characteristics, medical complications, and the anthropometric records of the T2DM patients predict the non-adherence [31, 38], our results revealed that the sex of the patients with diabetes is a significant predictor of non-adherence where the females were more likely to be non-adhered to medications. Our results also collaborated with the previous studies conducted on the factors associated with non-adherence to anti-diabetic drugs [17]. On the other hand, the proportion of non-adherence in our study was much higher than their counterparts. Our results are in accordance with preceding studies done in Kenya, Ethiopia, Uganda, and

| Table 4 Association between non-adherence and anthropometric measures and complications |
|---------------------------------|------------------|------------------|------------------|------------------|
| Variables | Non-adherence | Odd ratios, 95% CI | P-value |
|---------------------------------|------------------|------------------|------------------|
| Anthropometric data | | | |
| Blood pressure | | | |
| Normal | 52 | 48.6 | 1 | | 0.672 |
| Hypertension | 30 | 28.04 | 1.13 | .644 | 1.980 |
| BMI | | | |
| Underweight (< 18.5 kg/m²) | 10 | 9.35 | 1 | | 0.029* |
| Normal (18.5 kg/m²-24 kg/m²) | 32 | 29.91 | 1.64 | .88 | 3.1 |
| Overweight/obese (> 24 kg/m²) | 65 | 60.75 | 3.01 | 1.3 | 7.12 |
| Types of the medical drugs | | | |
| Single OHA | 59 | 55.14 | 1 | | 0.027* |
| OHA and Insulin | 29 | 27.1 | 0.43 | 0.22 | 0.86 |
| Insulin alone | 19 | 17.76 | 0.37 | 0.16 | 0.84 |
| Glycylated Hemoglobin (HbA1C) | | | |
| Good (<=7%) | 20 | 18.69 | 1 | | 0.013* |
| Poor (>7%) | 87 | 81.31 | 2.28 | 1.19 | 4.36 |
| Glycaemia (g/dl) | | | |
| Less than 170 g/dl | 11 | 10.28 | 1 | | 0.046* |
| 170–250 g/dl | 28 | 26.17 | 1.96 | 0.86 | 4.44 |
| More than250 g/dl | 68 | 63.55 | 0.567 | 0.27 | 1.18 |
| Presence of diabetes complications | | | |
| Retinopathy complication | | | |
| Yes | 48 | 44.86 | 1 | | 0.052 |
| No | 59 | 55.14 | 0.83 | 0.45 | 1.46 |
| Kidney disease | | | |
| Yes | 77 | 71.96 | 1 | | 0.216 |
| No | 30 | 28.04 | 0.68 | 0.36 | 1.26 |
| Skin infections | | | |
| Yes | 71 | 66.36 | 1 | | 0.035* |
| No | 36 | 33.64 | 0.541 | 0.31 | 0.96 |
| Presence of other chronic disease | | | |
| Yes | 99 | 92.52 | 1 | | 0.68 |
| No | 101 | 94.39 | 1.09 | 0.62 | 1.9 |

N indicates number of cases or frequency, % Percentage, OR Odds ratio, CI Confidence Intervals, OHA Oral Hypoglycemic Agents, DPCS Doctor- Patient Communication Scale, BMI Body Mass Index, HbA1C Glycosylated Hemoglobin

*p < 0.05

**p < 0.01

***p < 0.001
Table 5  Multivariate analysis for the associated factors of the non-adherence to medications

| Variables                                      | Non-adherence | 95% CI | P-value |
|------------------------------------------------|---------------|--------|---------|
| Sex                                            |               |        |         |
| Male                                           | 47            | 43.93  | 1       | 0.002** |
| Female                                         | 60            | 56.07  | 2.1     | 3.71 |
| Duration of diabetes                           |               |        |         |
| 1-3 years                                      | 49            | 45.79  | 1       | 0.042* |
| 4-10yrs                                        | 26            | 24.3   | 2.57    | 1.04 | 6.37 | 0.023* |
| More than 10 years                             | 32            | 29.91  | 1.03    | 0.34 | 3.12 | 0.031* |
| Education                                      |               |        |         |
| No formal education                            | 17            | 15.89  | 1       | 0.002* |
| Primary                                        | 51            | 47.66  | 3.56    | 1.12 | 11.28 | 0.031* |
| Secondary                                      | 39            | 36.45  | 2.96    | 1.11 | 7.87 | 0.030* |
| DPCS                                           |               |        |         |
| Good communication                             | 37            | 34.58  | 1       | 0.046* |
| Poor communication                             | 70            | 65.42  | 2.18    | 1.01 | 4.68 |
| Employment status                              |               |        |         |
| Jobless                                        | 28            | 26.17  | 1       | 0.061 |
| Public employee                                | 28            | 26.17  | 2.01    | 0.92 | 4.38 | 0.08 |
| Private                                        | 51            | 47.66  | 1.06    | 0.38 | 2.97 | 0.906 |
| Residence                                      |               |        |         |
| Kigali                                         | 76            | 71.03  | 1       | 0.089 |
| Out of Kigali                                  | 31            | 28.97  | 2.19    | 0.89 | 5.39 |
| Attitudes of the family members towards patients with T2DM |   |        |         |
| Very concerned                                 | 46            | 42.99  | 1       | 0.031* |
| Not concerned                                  | 37            | 34.58  | 0.15    | 0.4  | 5.5  | 0.54 |
| Perceived as burdensome                       | 24            | 22.43  | 5.8     | 1.3  | 25.7 | 0.021* |
| BMI                                            |               |        |         |
| Underweight (< 18.5 kg/m²)                     | 10            | 9.35   | 1       | 0.003** |
| Normal (18.5 kg/m²–24 kg/m²)                   | 32            | 29.91  | 5.17    | 1.63 | 16.37 | 0.005* |
| Overweight/obese (more than 24)                | 65            | 60.75  | 3.6     | 1.04 | 9.1  | 0.02* |
| Anti-diabetic medication                       |               |        |         |
| Single OHA                                     | 59            | 55.14  | 1       | 0.011* |
| OHA and Insulin                                | 29            | 27.1   | 0.59    | 0.24 | 1.42 | 0.023* |
| Insulin alone                                  | 19            | 17.76  | 0.26    | 0.09 | 0.74 | 0.011* |
| Glycosylated Hemoglobin (HbA1C)                |               |        |         |
| Good (w = < 7)                                 | 20            | 18.69  | 1       | 0.002** |
| Poor (> 7)                                     | 87            | 81.31  | 4.26    | 1.7  | 10.69 |
| Glycaemia (in g/dl)                            |               |        |         |
| Less than 170 g/dl                             | 11            | 10.28  | 1       | 0.0456* |
| 170–250 g/dl                                   | 28            | 26.17  | 3.17    | 1.06 | 9.5  | 0.04* |
| More than250 g/dl                              | 68            | 63.55  | 0.8     | 0.33 | 1.97 | 0.626 |
| Presence of diabetes complications             |               |        |         |
| Retinopathy complication                       |               |        |         |
| Yes                                            | 48            | 44.86  | 1       | 0.325 |
| No                                             | 59            | 55.14  | 1.43    | 0.7  | 2.9  |
| Skin infections                                |               |        |         |
| Yes                                            | 71            | 66.36  | 1       | 0.009** |
| No                                             | 36            | 33.64  | 0.36    | 0.17 | 0.77 |

\( N \) Frequency, \% Percentage, \( OR \) Odds ratio, \( CI \) Confidence Intervals, OHA Oral Hypoglycemic Agents, DPCS Doctor- Patient Communication Scale, BMI Body Mass Index, HbA1C Glycosylated Hemoglobin, rwf Rwandan francs

\( *p < 0.05 \)

\( **p < 0.01 \)

\( ***p < 0.001 \)
Those with secondary school education and university were almost more likely to experience non-adherence to medications when compared to those with no formal education. These findings were corresponding to the studies conducted in SSA such as in Uganda [31, 38]. Further, participants who took anti-diabetic drugs for 4–10 years and more than 10 years were more likely to experience non-adherence to medication when compared to those under anti-diabetic medications for less than 4 years. These results of our study are compatible to the prior studies [37], however, these results contradicted a study conducted Ethiopia and indicated that duration of diabetes, duration of treatment, taking of traditional medicine, other medications for other long term illness, and side effects of the drugs were not significantly associated with non-adherence to diabetic treatment agent [69, 80]. Then, poor social supports such as the supports from the family members, poor family relationship, and domestic violence are important predictors of non-adherence [81].

In our study, the T2DM patients who received combination of OHA and insulin drugs, and who received insulin had less odds of being non-adhered to medications as compared to those who took single. Additionally, our findings revealed that the T2DM whose family members considered them as their burdens were at greater risk to be non-adherent to anti-diabetic drugs when compared to those whose family members are very concerned in the management of the disease and its impact on their life. Most of these patients develop a worse life and became stigmatized. These results are supported by previous studies conducted on the prevalence and factors of non-adherence among T2DM patients [37, 82], despite, a study in Ethiopia challenged these findings [40]. This is because while availability and affordability of insulin remains the challenge that leads to an increase of non-adherence [40, 52], in Rwanda this medication is available and its cost is affordable. Further, participants with poor communication with their healthcare providers more likely experience non-adherence as compared to those with appropriate communication with their healthcare providers. These findings are in line with a study documented Uganda, Tanzania, Kenya, Ethiopia, in Bharat, Portugal and Kingdom of Saudi Arabia [48]. Although our bivariate reported a significant association between non-adherence and the residence, the multivariate analysis revealed no significant association between non-adherence and residence. Our results are not in accordance with the previous studies that documented that diabetes patients from the rural settings are more likely to non-adherence as compared to the urban [38, 51, 83]. Indeed, our results revealed that skin infection increases the odds to present non-adherence when compared to the patients with no skin infection. Our results are relevant to previous studies carried out and indicated the risk factors of non-adherence [17, 48].

This study has several limitations. First, it was primarily limited to a design, cross sectional study design, which was not able to determine the causal relationship for the non-adherence; however, this study was the first to report contributing factors of non-adherence among the T2DM patients. Second, the conception of adherence is large and it has several contributing factors (such as dietary the concept of adherence is broad since it includes the variables like dietary, health literacy, physical exercise, medications). Although, these variables are important contributing factors, we were not able to collect them which could cause underestimation or overestimation between the associated factors of non-adherence. Third, the study was conducted in one institution located in the urban area, Kigali city, while the T2DM patients from rural areas were not considered in this study. Thus, this could limit its generalisability; however, the sample size was large enough to assess the expected differences and associations between variables. So, we recommend further research on experimental study for determining the causal conclusion or indicating the effect of demographic, clinical and psychosocial factors on medical adherence over time to understand the long-term effects. However, these limitations, some strengths warrant discussion. First; this is the first study conducted to indicate the prevalence of non-adherence and its factors among T2DM at Clinique Medicale Fraternite. Second; the present study utilized validated instruments to assess the level of adherence and its associated factors.

**Conclusion**

More than a half (53.5%) of T2DM patients was non-adherent to their anti-diabetic medications. Different contributing factors were identified such as sex, education, BMI, type of medications, glycaemia level, attitudes of family members toward the T2DM patients, duration of disease, HbA1C, skin infections, and poor communication with the healthcare providers. Tackling this health concern of non-adherence should be a priority agenda for policy makers and researchers who can have a great contribution to a reduction of the associated factors through collaboration with healthcare providers and pharmacists. Thus, our results should be used a baseline information to the policy makers, concerned governmental bodies such as Ministry of Health and different stakeholders that workaround rational medicine use to assess the currently available policies regarding rational use of medicines. Health facility is recommended to provide health education and counseling to the T2DM patients targeting the patients with suboptimal adherence for intensified
adherence counseling which is essential for promoting health of patients with diabetes. More efforts is needed to increase adherence to medication by training health-care providers about an effective communication with the patients and health education to reinforce patients in knowing full benefits of prescribed therapies. Further study on psychosocial and cultural influences on non-adherence, and prospective study design for determining the risk factors of non-adherence are recommended.

Acknowledgements
All authors of this study thank all participants who took part in this study.

Authors’ contributions
JDM conceived of the analysis, collected the data, performed the statistical analysis, and conducted the literature review. MU contributed to the conception, data analysis, and interpretation of the findings and provided manuscript feedback. AN led statistical analysis, contributed to the conceptualization and co-supervised the study and provided the manuscript feedback. FKS contributed to method design and assisted with the analysis. EB drafted the manuscript and contributed to the data acquisition and statistical analysis. All authors read and approved the final version of the article and agreed to the journal for submitting a manuscript.

Funding
This study did not receive any funding.

Availability of data and materials
The datasets generated during and analyzed are available from the corresponding author upon reasonable request. As one of the research questionnaires “Morisky-Green-Levine Scale (MGLS) designed by Morisky is shared upon the approval of its founder, the dataset is not publicly available.

Declarations

Ethics approval and consent to participate
The study was approved by the Institutional Review Board, College of Medicine and Health Sciences (IRB/CMHS) at the University of Rwanda with the approval number (N˚: 460/CMHS IRB/2019). Authorization to access medical and Health Sciences (IRB/CMHS) at the University of Rwanda with the Ethics approval and consent to participate Declarations
All authors of this study thank all participants who took part in this study.

Authors declared that they have no competing interest in this work.

Competing interests
Authors declared that they have no competing interest in this work.

Author details
1Department of Epidemiology and Biostatistics, School of Public Health, University of Rwanda, Kigali, Rwanda. 2Programme of Sociotherapy, Prison Fellowship Rwanda (PFR), Kigali, Rwanda. 3College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda.

Received: 12 December 2021 Accepted: 17 August 2022
Published online: 31 August 2022

References
1. Davidson S. The Principles and Practice of Medicine. 19th ed. Davidson S, editor. Philadelphia: Churchill Livingstone, 2005.
2. Center for Diseases Control (CDC). National Diabetes Statistics Report. 2020. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.
3. Zheng Y, Ley S, Hu F. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88.
4. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates to the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–21. https://doi.org/10.1016/j.diabet.2011.10.029.
5. Cho N, Shaw J, Karuranga S, Huang Y, Fernandes JD d R, Ohringe A, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabet.2018.02.023.
6. Brunton S, Gough S, Hicks D, Weng J, Moghissi E, Peyrot M. A look into the future: improving diabetes care by 2015. Curr Med Res Opin. 2011;27(Suppl 1):65–72.
7. Mirahmadizadeh A, Khoshridavar H, Seif M, Sharifi MH. Adherence to medication, diet and physical activity and the associated factors amongst patients with type 2 diabetes. Diabetes Ther. 2020;11(2):479–94. https://doi.org/10.1007/s13300-019-00750-8.
8. EI-Hadiyah TM, Mustafa Madani A, Abdelsalam HM, Khidir Yousef A. Factors affecting medication non adherence in Type 2 Sudanese diabetic patients. Pharmacoil Pharm. 2016;07(04):141–6. https://doi.org/10.4236/pp.2016.74018.
9. Huang YM, Shianbola OC, Chan HY, Smith PD. Patient factors associated with diabetes medication adherence at different health literacy levels: a cross-sectional study at a family medicine clinic. Postgrad Med. 2020;132(4):329–36.
10. Huang J, Ding S, Xiong S and Liu Z. Medication Adherence and Associated Factors in Patients With Type 2 Diabetes: A Structural Equation Model. Front Public Health. 2021;9:730845. https://doi.org/10.3389/fpubh.2021.730845.
11. International Diabetes Federation (IDF). The International Diabetes Federation (IDF) response to the WHO first draft of the Framework for country action across sectors for health and health equity, March 2015. Available from: https://www.who.int/healthpromotion/idf/pdf.uae1.pdf.
12. World Health Organization. Diabetes. Geneva, Switzerland; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes.
13. Cho N, Shaw J, Karuranga S, Huang Y, Fernandes JD d R, Ohringe A, et al IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. Available from: https://doi.org/10.1016/j.diabet.2018.02.023.
14. Terzic A, Ph D, Waldman S, Ph D. Hot topic chronic diseases: the emerging pandemic. Clin Transl Sci. 2020;4(3):225–6.
15. Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, Johnson KA, et al. Challenges and opportunities in global mental health: a research-to-practice perspective. Curr Psychiatry Rep. 2017;19(5):28.
16. Gholamaliei B, Karimi-Shahjariani A, Rosanvand R, Rezapour-Shahkolaei I. Medication adherence and its related factors in patients with type 2 diabetes. J Educ Community Heal. 2016;2(4):3–12.
17. Abate TW. Medication non-adherence and factors among diabetes patients in Felege Hiwot Referral Hospital, Bahir Dar city administration, Northwest Ethiopia. BMC Res Notes. 2019;12:175. https://doi.org/10.1186/s13104-019-4205-4.
18. Atun J, Stokes A, Goehler A, Houinato D, Houelhounou C. Diabetes diagnosis and care in sub-Saharan Africa: pooled analysis of individual data from 12 countries. Lancet Diabetes Endocrinol. 2016;67:89. https://doi.org/10.1016/S2213-8587(16)30381-4.
19. Shayo FK, Shayo SC. Availability and readiness of diabetes health facilities to manage tuberculosis in Tanzania: a path towards integrating tuberculosis-diabetes services in a high burden setting? BMC Public Health. 2019;19:1–7.
20. Dirk L, Henrik F, Mwaniki D, Kilonzo B, Teteris I, Boit M. Prevalence of glucose intolerance and associated risk factors in rural and urban populations of different ethnic groups in Kenya. Diabetes Res Clin Pract. 2009;84(3):303–10.
21. Birawba C, Bwambale MF, Waisswa P, Mayega RW. Quality and barriers of outpatient diabetes care in rural health facilities in Uganda – a mixed methods study. BMC Health Serv Res. 2019;19(706):1–10. https://doi.org/10.1186/s12913-019-4535-4.
22. Maja-Tassou C, Katte JC, Mbaya JC. Economic Impact of Diabetes in Africa. Curr Diab Rep. 2019;19(2). https://doi.org/10.1007/s11892-019-1124-7.
23. Kinimi E, Balthazar S, Kituo S, Msalika S. Prevalence of diabetes mellitus in patients seeking medical care at Morogoro Regional Referral Hospital in Tanzania. Tanzan J Health Res. 2017;19(4):1–8. https://doi.org/10.4314/thrh.v19i4.8

24. Stanifer JW, Cleland CR, Makuka GJ, Egger R, Maro V, Maro H, et al. Prevalence, risk factors, and complications of diabetes in the Kili-manjaro Region - a population-based study from Tanzania. PLoS One. 2016;11(10):1–13.

25. Ministry of Health. Rwanda non-communicable diseases risk factors report. Kigali, Rwanda; 2015. Available from: https://www.who.int/ncds/surveillance/Rwanda_2012_STEPS_Report.pdf

26. Al-Ajlan A. Emerging challenges of diabetes. Middle East J Fam Med. 2009;7(6):22–7.

27. Bi Y. Advanced research on risk factors of type 2 diabetes. Diabetes Metab Res Rev. 2012;28(2):32–9. https://doi.org/10.1002/dmrr.2352.

28. Abdullah M, Mansour A. The prevalence and risk factors of type 2 Diabetes Mellitus (DM2) in a semi-urban Saudi population. Int J Environ Res Public Health. 2020;17(7):1–8. https://doi.org/10.3390/ijerph.17010007.

29. Abdulazeez FI, Omole M, Ojulari SL. Medication Compliance amongst type 2 Diabetic Patients in Ilorin, Nigeria Medication Compliance amongst Diabetic Patients in Ilorin, Nigeria Abstract: IOSR J Dent Med Sci. 2015;2:6–2.

30. Ostergren D, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:48–57.

31. Waari GK. Assessment of medication non-adherence and associated factors among type 2 diabetes mellitus patients on follow-up at Kenyatta National Hospital, Kenya. Pan Afr Med J. 2018;8688. https://doi.org/10.11604/pamj.2018.8688.12639.

32. WHO. Global report on diabetes. World Health Organization (WHO), editor. Geneva, Switzerland: World Health Organization; 2016. Available from: http://www.who.int/about/licensing/. Retrieved on 12th November 2021

33. Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.

34. Blackburn D, Swidrovich J, Lemstra M. Non-adherence in type 2 diabetes: practical considerations for interpreting the literature. Patient Prefer Adherence. 2013;7:183–9. https://doi.org/10.2147/PPA.S30613.

35. Kassahun A, Gashe F, Mulisa E, Rike WA. Nonadherence and factors affecting adherence of diabetic patients to anti-diabetic medication in Assela General Hospital, Oromia Region. Ethiopia J Pharm Bioalied Sci. 2016;8(2):124–9.

36. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Retrospective cohort study. Diabet Med. 2002;19:279–84.

37. Waari GK. Assessment of medication non-adherence and associated factors among type 2 diabetes mellitus patients attending the diabetic clinic at Kenyatta National Hospital, Jomo Kenyatta University. 2019. http://ir.jkuat.ac.ke/bitstream/handle/123456789/5131/Diabetes%20MedicationAdherence.pdf?sequence=1&isAllowed=y.

38. Kalyango JN, Owino E, Namighbua AP. Non-adherence to diabetes treatment at Mulago Hospital in Uganda - prevalence and associated factors. Afr J Health Sci. 2008;8(2):67–73.

39. Rwegerera GM. Adherence to anti-diabetic drugs among patients with Type 2 diabetes mellitus at Muhimbili National Hospital, Dar es Salaam, Tanzania- a cross-sectional study. Pan Afr Med J. 2014;8688:1–9.

40. Amunde LN, Tindong M, Ngwasiri CA, Aminde JA, Njim T, Fondong AA, et al. Adherence to antidiabetic medication and factors associated with non-adherence among patients with type 2 diabetes mellitus in two regional hospitals in Cameroon. BMC Endocr Disord. 2019;19(35).

41. Rickles NM, Brown TA, McGown MS, Snyder ME, White KA. Adherence: a review of education, research, practice, and policy in the United States. Pharmac Pract (Granada). 2010;8(1):1–17.

42. Lin L, Sun Y, Heng BH, El D, Chev K. Medication adherence and glycemic control among newly diagnosed diabetes patients. BMJ Open Diab Res Care. 2017;5(00429):1–9.

43. Id NMA, Scott NW, Aljadhey HS, Araujo-soares V, Id AA, Id MCW. Medication adherence among patients with Type 2 diabetes: a mixed methods study. PLoS One. 2018;13(12):1–18.

44. Ayah R, Joshi M, Waranjua R, Njua E, Otieno C, Njeru E. A population-based survey of prevalence of diabetes and correlates in an urban slum community in Nairobi, Kenya. BMC Public Health. 2013;13:371.

45. Azevedo M, All A. Diabetes in Sub-Saharan Africa: Kenya, Mali, Mozambique, Nigeria, South Africa and Zambia. Int J Diabetes Dev Ctries. 2008;28(4):101–8.

46. Adams D. Autoimmune destruction of pericytes as the cause of diabetic retinopathy. Clin Ophthalmol. 2008;2(2):295–8. https://doi.org/10.2147/ophth.s2629.

47. Riaz M, Baist A, Fawwad A, Ahmedani M, Rizvi Z. Factors associated with non-adherence to Insulin in patients with Type-1 diabetes. Pak J Med Sci. 2013;30(2):11–3.

48. International Diabetes Federation. IDF Diabetes Atlas. Seventh ed. International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org

49. Netsanet F, Abebe M. Risky sexual behaviors and associated factors among male and female students in Jimma Zone Preparatory Schools, South West Ethiopia: comparative study. Ethiop J Health Sci. 2014;24(1):59–68.

50. Kamuhabwa AR, Charles E. Predictors of poor glycemic control in type 2 diabetic patients attending public hospitals in Dar es Salaam. Drug Healthc Patient Saf. 2014;6:155–65. https://doi.org/10.2147/DHPS.S68786.

51. Gill G, Gill G. Diabetes in Africa - puzzles and challenges. Indian J Endocrinol Metab. 2014;18(3):249–51. https://doi.org/10.4103/2239-8210.131111.

52. Lau D, Nau D. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Am Diabetes Assoc. 2004;27:149–53.

53. Donnan P, MacDonald T, Morris A. Adherence to prescribed oral hypoglycemic medication in a population of patients and Type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279–84.

54. Shenuolikar R, Balkrishnan R. Oral antidiabetic medication adherence and health care utilization among medicad-enrolled type 2 diabetic patients beginning monotherapy. Am Diabetes Assoc. 2008;31(2).

55. Sanati T, Vaezi A, Jambarsang S. Medication Adherence Status and its Related Factors among Older Adults in Yazd. Iran Elder Heal J. 2020;6(2):85–90.

56. Delamater A. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7.

57. Delamater A. Improving patient adherence. Clin Diabetes. 2006;24(2):71–7.

58. Peyrot M, Rubin R, Lauritzen T, Snoek F, Matthews D, Skovlund S. The Edinburgh Diabetes Patient Preference and Acceptance Survey (Ed-DPAS): developing a tool for surveying diabetes patients about diabetes care. Patient Prefer Adherence. 2012;6:491–9.

59. Benner J, Glynn R, Mougou H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. J Am Boards Fam Pract. 2002;15:125–31.

60. Srivastava S. Diabetes Mellitus: diagnosis and management guidelines. J Int Med Sci Acad. 2015;28(11):47–50.

61. World Health Organization (WHO). Management of Diabetes Mellitus standards of care and clinical practice guidelines. Alwan AAS, editor. Alexandria, 1994. 1–7 p. https://applications.emro.who.int/dsaf/dsaf509.pdf?sequence=1&isAllowed=y.

62. Benner J, Glynn R, Mougou H, Neumann P, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. J Am Med Assoc. 2002;288(4):455–61.

63. Mayberry LS, Osborn CY. Family support, medication adherence, and glycemic control among adults with type 2 Diabetes. Diabetes Care. 2012;35(6):1239–45.

64. Piette J, Hesler M, Wagner T. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27(2):384–91.

65. Lee VWY, Leung PY. Glycemic Control and medication compliance in diabetic patients in a Pharmacist-Managed Clinic in Hong Kong. Am J Heal Pharm. 2003;60(24):2593.

66. World Diabetes Foundation (WDF). Global diabetes trends- begin to show in Rwanda. Kigali, Rwanda; 2012. Available from: https://www.worlddiabetesfoundation.org/news/global-diabetes-trends-begin-show-rwanda

67. Zullig L, Gellad W, Moaddbeh J, Crowley M, Shrank W, Granger B. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:1–6.

68. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60.
69. Boshe BD, Yimar GN, Dadhi AE, Bededa WK. The magnitude of non-adherence and contributing factors among adult outpatient with Diabetes Mellitus in Dilla University Referral Hospital, Gedilo, Ethiopia. PLoS One. 2021;16(3 March):1–15.

70. Schneider DE, Tucker RK. Measuring Communicative satisfaction in Doctor-Patient Relations: The Doctor-Patient Communication Inventory. Health Commun. 2009;4(1):19–28.

71. Bosson J, Foote A. A scale assessing doctor-patient communication in a context of acute conditions based on a systematic review. PLoS One. 2018;13(2):1–16 e0192306.

72. Eveleigh RM, Muskens E, Van RH, Van DJ, Van RE, Lucassen P. An overview of 19 instruments assessing the doctor-patient relationship: different models or concepts are used. J Clin Epidemiol. 2012;65(1):10–5. https://doi.org/10.1016/j.jclinepi.2011.05.011.

73. Beyhaghi H, Reeve BB, Rodgers JE, Stearns SC. Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants. Value Heal. 2016;19(8):996–1001.

74. Morisky DE, Levine DM, Green LW, Shapiro S, Russell RP, Smith CR. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Heal. 1983;73(2):153–62. https://doi.org/10.2105/ajph.73.2.153.

75. Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care. 1986;24:67–74.

76. Saktisong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky medication adherence scale in patients with type 2 diabetes. Ann Pharmacother. 2009;43(5):950–7. https://doi.org/10.1345/aph.1L453.

77. Koschack J, Marx G, Schnakenberg J, Kochen MM, Himmel W. Comparison of two self-rating instruments for medication adherence assessment in hypertension revealed insufficient psychometric properties. J Clin Epidemiol. 2010;63(3):299–306.

78. World Health Organization. Child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and 444 for-length, weight-for-height and body mass index-for-age: methods and 444 development. Geneva, Switzerland; 2006.

79. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–9.

80. Teklay G, Hussein J, Tesfaye D. Non-adherence and associated factors among type 2 diabetic patients at Jimma University specialized Hospital South West Ethiopia. J Med Sci. 2013;13:578–84.

81. Gonzalez J, Schneider H, Wexler D, Psaros C. Validity of medication adherence self-reports in adults with type 2 diabetes. Diabetes Care. 2013;36(4):831–7.

82. Albuquerque C, Correia C, Ferreira M. Adherence to the therapeutic regime in person with type 2 diabetes. Procedia - Soc Behav Sci. 2015;171(16):350–8.

83. Manjusha S, Madhu P, Atmatam P, Amit M, Ronak S. Medication adherence to antidiabetic therapy in patients with type 2 diabetes mellitus. Int J Pharm Pharm Sci. 2014;6(2):564–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.